Switch to:
Also traded in: Canada, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.02
VRX's Cash to Debt is ranked lower than
98% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. VRX: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
VRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.24 Max: No Debt
Current: 0.02
Equity to Asset 0.12
VRX's Equity to Asset is ranked lower than
96% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. VRX: 0.12 )
Ranked among companies with meaningful Equity to Asset only.
VRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.56 Max: 0.85
Current: 0.12
0.12
0.85
Interest Coverage 0.98
VRX's Interest Coverage is ranked lower than
93% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. VRX: 0.98 )
Ranked among companies with meaningful Interest Coverage only.
VRX' s Interest Coverage Range Over the Past 10 Years
Min: 0.17  Med: 4.31 Max: 121.91
Current: 0.98
0.17
121.91
F-Score: 4
Z-Score: 0.34
M-Score: -2.26
WACC vs ROIC
8.72%
-10.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.49
VRX's Operating margin (%) is ranked higher than
69% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. VRX: 14.49 )
Ranked among companies with meaningful Operating margin (%) only.
VRX' s Operating margin (%) Range Over the Past 10 Years
Min: -9.32  Med: 15.51 Max: 24.68
Current: 14.49
-9.32
24.68
Net-margin (%) -2.97
VRX's Net-margin (%) is ranked lower than
77% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. VRX: -2.97 )
Ranked among companies with meaningful Net-margin (%) only.
VRX' s Net-margin (%) Range Over the Past 10 Years
Min: -17.62  Med: 8.77 Max: 26.4
Current: -2.97
-17.62
26.4
ROE (%) -5.21
VRX's ROE (%) is ranked lower than
75% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. VRX: -5.21 )
Ranked among companies with meaningful ROE (%) only.
VRX' s ROE (%) Range Over the Past 10 Years
Min: -20.2  Med: 8.21 Max: 18.27
Current: -5.21
-20.2
18.27
ROA (%) -0.75
VRX's ROA (%) is ranked lower than
71% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. VRX: -0.75 )
Ranked among companies with meaningful ROA (%) only.
VRX' s ROA (%) Range Over the Past 10 Years
Min: -3.88  Med: 2.43 Max: 13.02
Current: -0.75
-3.88
13.02
ROC (Joel Greenblatt) (%) 31.19
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. VRX: 31.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -69.93  Med: 73.40 Max: 144.45
Current: 31.19
-69.93
144.45
Revenue Growth (3Y)(%) 53.80
VRX's Revenue Growth (3Y)(%) is ranked higher than
95% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. VRX: 53.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.9  Med: 27.70 Max: 55.3
Current: 53.8
-10.9
55.3
EBITDA Growth (3Y)(%) 67.20
VRX's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. VRX: 67.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.7  Med: 17.70 Max: 113.3
Current: 67.2
-35.7
113.3
EPS Growth (3Y)(%) 45.80
VRX's EPS Growth (3Y)(%) is ranked higher than
89% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. VRX: 45.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -39  Med: 11.70 Max: 83.3
Current: 45.8
-39
83.3
» VRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

VRX Guru Trades in Q2 2015

Kyle Bass 10,198 sh (New)
George Soros 9,254 sh (New)
Ken Fisher 1,828 sh (New)
Steven Cohen 42,900 sh (New)
John Paulson 9,000,000 sh (+339.02%)
Jeremy Grantham 1,708,746 sh (+47.82%)
Andreas Halvorsen 4,616,738 sh (+13.76%)
Private Capital 302,715 sh (+2.50%)
Glenn Greenberg 2,500 sh (unchged)
Bill Ackman 19,473,933 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Ruane Cunniff 33,884,050 sh (-0.60%)
Glenn Greenberg 5,701,010 sh (-2.99%)
Steve Mandel 5,310,143 sh (-4.66%)
Chris Davis 1,762,238 sh (-6.12%)
Joel Greenblatt 61,178 sh (-6.64%)
Lou Simpson 1,728,265 sh (-8.97%)
First Eagle Investment 1,055,332 sh (-11.45%)
Jana Partners 1,342,723 sh (-14.56%)
Wallace Weitz 716,730 sh (-21.86%)
Jeff Ubben 14,994,261 sh (-22.65%)
Diamond Hill Capital 130,617 sh (-27.23%)
Lee Ainslie 756,609 sh (-40.70%)
Jim Simons 107,789 sh (-77.35%)
» More
Q3 2015

VRX Guru Trades in Q3 2015

Leon Cooperman 484,915 sh (New)
Jeremy Grantham 8,176,586 sh (+378.51%)
Joel Greenblatt 88,677 sh (+44.95%)
Steve Mandel 7,461,780 sh (+40.52%)
Diamond Hill Capital 169,542 sh (+29.80%)
Lou Simpson 1,952,983 sh (+13.00%)
Andreas Halvorsen 4,993,353 sh (+8.16%)
Lee Ainslie 811,361 sh (+7.24%)
Ken Fisher 1,833 sh (+0.27%)
Ruane Cunniff 33,922,192 sh (+0.11%)
First Eagle Investment 1,055 sh (unchged)
Bill Ackman 19,473,933 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
First Eagle Investment 1,055,332 sh (unchged)
Steven Cohen Sold Out
George Soros Sold Out
Jana Partners Sold Out
Jim Simons Sold Out
Kyle Bass Sold Out
John Paulson 8,890,000 sh (-1.22%)
Private Capital 296,931 sh (-1.91%)
Glenn Greenberg 5,577,892 sh (-2.16%)
Wallace Weitz 630,155 sh (-12.08%)
Chris Davis 1,509,122 sh (-14.36%)
» More
Q4 2015

VRX Guru Trades in Q4 2015

Jana Partners 1,565,935 sh (New)
Steven Cohen 17,900 sh (New)
Chris Davis 3,784,012 sh (+150.74%)
Diamond Hill Capital 301,374 sh (+77.76%)
Andreas Halvorsen 7,793,397 sh (+56.08%)
First Eagle Investment 1,640,132 sh (+55.41%)
John Paulson 13,265,900 sh (+49.22%)
Lou Simpson 2,698,614 sh (+38.18%)
Private Capital 336,306 sh (+13.26%)
Glenn Greenberg 6,252,331 sh (+12.09%)
Ruane Cunniff 35,375,610 sh (+4.28%)
Jeff Ubben 14,994,261 sh (unchged)
First Eagle Investment 2,000 sh (unchged)
First Eagle Investment 2,500 sh (unchged)
Leon Cooperman Sold Out
Lee Ainslie Sold Out
Joel Greenblatt Sold Out
Wallace Weitz Sold Out
Ken Fisher Sold Out
Bill Ackman 16,591,122 sh (-14.80%)
Steve Mandel 5,829,079 sh (-21.88%)
Jeremy Grantham 4,393,848 sh (-46.26%)
» More
Q1 2016

VRX Guru Trades in Q1 2016

Francis Chou 976,843 sh (New)
Arnold Schneider 66,000 sh (New)
David Tepper 945,000 sh (New)
Joel Greenblatt 15,088 sh (New)
Steven Cohen 3,574,900 sh (+19871.51%)
Chris Davis 7,240,337 sh (+91.34%)
Diamond Hill Capital 571,305 sh (+89.57%)
Bill Ackman 21,591,122 sh (+30.14%)
Private Capital 342,916 sh (+1.97%)
John Paulson 13,284,800 sh (+0.14%)
Jeff Ubben 14,994,261 sh (unchged)
First Eagle Investment 11,970 sh (unchged)
Steven Cohen 529,600 sh (unchged)
John Paulson 169,800 sh (unchged)
John Paulson 73,100 sh (unchged)
Jana Partners Sold Out
Jeremy Grantham Sold Out
Andreas Halvorsen Sold Out
Steve Mandel Sold Out
Lou Simpson 2,591,399 sh (-3.97%)
First Eagle Investment 1,495,332 sh (-8.83%)
Ruane Cunniff 30,308,449 sh (-14.32%)
Glenn Greenberg 2,034,281 sh (-67.46%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico, VRX.Switzerland, 0QYW.UK,
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

Valeant Pharmaceuticals International Inc was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act effective June 29, 2005. In connection with the acquisition of Valeant Pharmaceuticals International (Valeant) in September 2010, Biovail was renamed Valeant Pharmaceuticals International, Inc. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products OTC, and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.

Ratios

vs
industry
vs
history
Forward P/E 2.36
VRX's Forward P/E is ranked higher than
98% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. VRX: 2.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 6.30
VRX's Price/Owner Earnings (ttm) is ranked higher than
92% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. VRX: 6.30 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
VRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.64  Med: 21.37 Max: 411.19
Current: 6.3
4.64
411.19
P/B 1.46
VRX's P/B is ranked higher than
73% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. VRX: 1.46 )
Ranked among companies with meaningful P/B only.
VRX' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 2.99 Max: 14.44
Current: 1.46
1.03
14.44
P/S 0.88
VRX's P/S is ranked higher than
84% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. VRX: 0.88 )
Ranked among companies with meaningful P/S only.
VRX' s P/S Range Over the Past 10 Years
Min: 0.85  Med: 3.99 Max: 10.48
Current: 0.88
0.85
10.48
PFCF 4.77
VRX's PFCF is ranked higher than
92% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. VRX: 4.77 )
Ranked among companies with meaningful PFCF only.
VRX' s PFCF Range Over the Past 10 Years
Min: 2.67  Med: 13.44 Max: 450.3
Current: 4.77
2.67
450.3
POCF 4.13
VRX's POCF is ranked higher than
91% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. VRX: 4.13 )
Ranked among companies with meaningful POCF only.
VRX' s POCF Range Over the Past 10 Years
Min: 4.04  Med: 10.94 Max: 47.76
Current: 4.13
4.04
47.76
EV-to-EBIT 29.60
VRX's EV-to-EBIT is ranked lower than
69% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. VRX: 29.60 )
Ranked among companies with meaningful EV-to-EBIT only.
VRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1217.7  Med: 12.80 Max: 379.7
Current: 29.6
-1217.7
379.7
EV-to-EBITDA 10.25
VRX's EV-to-EBITDA is ranked higher than
74% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. VRX: 10.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31  Med: 14.10 Max: 106.7
Current: 10.25
-31
106.7
Shiller P/E 81.95
VRX's Shiller P/E is ranked lower than
74% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. VRX: 81.95 )
Ranked among companies with meaningful Shiller P/E only.
VRX' s Shiller P/E Range Over the Past 10 Years
Min: 8.9  Med: 43.14 Max: 469.31
Current: 81.95
8.9
469.31
Current Ratio 1.04
VRX's Current Ratio is ranked lower than
87% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. VRX: 1.04 )
Ranked among companies with meaningful Current Ratio only.
VRX' s Current Ratio Range Over the Past 10 Years
Min: 0.91  Med: 1.57 Max: 6.13
Current: 1.04
0.91
6.13
Quick Ratio 0.80
VRX's Quick Ratio is ranked lower than
85% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. VRX: 0.80 )
Ranked among companies with meaningful Quick Ratio only.
VRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.22 Max: 5.66
Current: 0.8
0.78
5.66
Days Inventory 154.69
VRX's Days Inventory is ranked lower than
69% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. VRX: 154.69 )
Ranked among companies with meaningful Days Inventory only.
VRX' s Days Inventory Range Over the Past 10 Years
Min: 115.82  Med: 138.97 Max: 157.92
Current: 154.69
115.82
157.92
Days Sales Outstanding 98.94
VRX's Days Sales Outstanding is ranked lower than
66% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. VRX: 98.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.41  Med: 74.31 Max: 106.05
Current: 98.94
43.41
106.05
Days Payable 64.60
VRX's Days Payable is ranked lower than
55% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. VRX: 64.60 )
Ranked among companies with meaningful Days Payable only.
VRX' s Days Payable Range Over the Past 10 Years
Min: 61.25  Med: 77.59 Max: 128.67
Current: 64.6
61.25
128.67

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.53
VRX's Price/Projected FCF is ranked higher than
93% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. VRX: 0.53 )
Ranked among companies with meaningful Price/Projected FCF only.
VRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.39  Med: 1.84 Max: 8.81
Current: 0.53
0.39
8.81
Price/Median PS Value 0.22
VRX's Price/Median PS Value is ranked higher than
97% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. VRX: 0.22 )
Ranked among companies with meaningful Price/Median PS Value only.
VRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 1.35 Max: 4.69
Current: 0.22
0.57
4.69
Earnings Yield (Greenblatt) (%) 3.32
VRX's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. VRX: 3.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 4.90 Max: 22.8
Current: 3.32
0.3
22.8
Forward Rate of Return (Yacktman) (%) 87.94
VRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. VRX: 87.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.5  Med: 16.70 Max: 92.5
Current: 87.94
2.5
92.5

More Statistics

Revenue (TTM) (Mil) $10,447
EPS (TTM) $ -0.84
Beta0.15
Short Percentage of Float6.53%
52-Week Range $23.55 - 263.81
Shares Outstanding (Mil)343.02

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 14,042 15,230 16,237
EPS ($) 11.17 14.60 14.64
EPS without NRI ($) 11.17 14.60 14.64
EPS Growth Rate
(3Y to 5Y Estimate)
0.00%
» More Articles for NYSE:VRX

Headlines

Articles On GuruFocus.com
David Tepper Exits Apple, Buys Facebook and Energy May 17 2016 
Francis Chou Takes Stake in Valeant, Coal Company May 13 2016 
Bill Ackman Comments on Valeant May 11 2016 
Bill Ackman Discusses Each of His Holdings in Pershing's Q1 Letter May 11 2016 
Ackman Selling Zoetis, But Other Firms Are Jumping In May 10 2016 
Hedge Fund Gurus Struggle With Low Returns, Criticize Industry May 10 2016 
Valeant Shares Fall After Company Forms Committee to Oversee Drug Pricing May 06 2016 
Ackman Defends Valeant From Buffett, Munger Criticism May 04 2016 
Best Moments From Buffett's Annual Berkshire Shareholder Meeting May 04 2016 
Ackman to Testify About Valeant Before Senate Apr 26 2016 

More From Other Websites
SEC raises concerns about Valeant's use of "Non-GAAP" measures May 24 2016
SEC Asked Valeant to Change How It Reported Deal Costs, Tax May 24 2016
The SEC is looking at Valeant’s ‘potentially misleading’ accounting practices May 24 2016
Valeant Pharmaceuticals: The SEC is 'Concerned' With Valeant's Accounting. Should You Be Too? May 24 2016
Valeant to Evaluate Sales of Noncore Assets May 24 2016
One Reason Valeant (VRX) Stock is Down Today May 24 2016
Valeant Pharmaceuticals: It's Complicated May 24 2016
The Social Media Index: Today’s Market Sentiment Indicator May 23 2016
Sequoia Fund Sets Portfolio Limits To Guard Against Valeant Redux May 23 2016
Here's a Reason Why Valeant (VRX) Stock Is Down Today May 23 2016
Valeant: Turning Over a New Guidance Leaf? May 23 2016
Valeant CEO Papa plans to lower debt by more than $1.5 billion in 2016 May 23 2016
Valeant CEO Papa plans to lower debt by more than $1.5 billion in 2016 May 23 2016
Valeant CEO Papa plans to lower debt by more than $1.5 bln in 2016 May 23 2016
Why Are These Five Stocks in Spotlight on Monday? May 23 2016
Valeant's new CEO: 'Did we do that? Yes. Was it a mistake? Yes.' May 23 2016
Valeant New CEO Papa Sees ‘Speed Bumps’ in Dermatology May 23 2016
Morning Movers: Alcoa Jumps on Merrill Upgrade; Monsanto Climbs on Bayer Bid May 23 2016
Valeant's new CEO Papa says there is a lot to work on May 23 2016
Bausch + Lomb Wins Walmart "Supplier of the Year" Award May 23 2016
Valeant Gets Default Notice, Senior VP Resigns (VRX) May 23 2016
Painful Valeant Debacle Spurs Improvements at Sequoia May 23 2016
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders May 19 2016
Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference May 18 2016
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters May 16 2016
Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel May 16 2016
Valeant Pharma promises to do better with deadlines May 09 2016
Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First... May 09 2016
Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs May 05 2016
Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM May 05 2016
Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals May 03 2016
Warren Buffett says more likely to buy IBM shares than sell - CNBC May 02 2016
Warren Buffett says more likely to buy IBM shares than sell - CNBC May 02 2016
Buffett says drugmaker Valeant had flawed business model May 02 2016
Valeant files overdue financial report, ending debt default Apr 29 2016
Valeant files overdue financials, averts debt default Apr 29 2016
Valeant Announces Nominees For Election To Board Of Directors Apr 29 2016
Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015 Apr 29 2016
Valeant files overdue financials, averts debt default Apr 29 2016
Lawmakers blast Valeant for price-gouging tactics Apr 27 2016
Business Highlights Apr 27 2016
Senate hearing into Valeant includes top hedge fund investor Apr 26 2016
Valeant Pharma picks Perrigo leader to become next CEO Apr 25 2016
Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Apr 25 2016
Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K... Apr 22 2016
Report: Valeant finalizing contract with Perrigo's CEO Apr 22 2016
US open: Stocks decline as investors digest data Apr 15 2016
Exclusive: Valeant calls in investment banks to weigh options - sources Apr 14 2016
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Apr 13 2016
Valeant CEO agrees to be deposed in Senate drug price probe Apr 13 2016
Business Highlights Apr 11 2016
Valeant has told outgoing CEO to cooperate with Senate Apr 11 2016
Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate... Apr 11 2016
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Apr 07 2016
Valeant completes accounting review, finds no new issues Apr 05 2016
Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting... Apr 05 2016
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR Apr 04 2016
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR Apr 04 2016
Valeant directors, CEO ordered to cease trading shares Mar 31 2016
Business Highlights Mar 30 2016
LPC - Valeant pays up for flexibility Mar 30 2016
Valeant seeks more time to file annual report Mar 30 2016
Valeant tries to delay release of financial statements Mar 30 2016
US stocks near flat ahead of Yellen speech, jobs data Mar 28 2016
US STOCKS-Wall St ends flat as recent rally spurs caution Mar 21 2016
Valeant CEO Pearson to exit, Ackman to join board Mar 21 2016
US STOCKS-Wall St flat as Fed still dominates investor sentiment Mar 21 2016
S&P says it may cut Ackman hedge fund's rating Mar 17 2016
US STOCKS-Wall St dips as healthcare lags before Fed statement Mar 15 2016
Valeant shares plunge 49% on default warning, outlook Mar 15 2016
US STOCKS-Health, materials shares drag on Wall St in lull before Fed news Mar 15 2016
Valeant shares plunge 45% on revised forecasts Mar 15 2016
US STOCKS-S&P 500 ticks above 2,000 as energy offsets tech slide Mar 07 2016
US STOCKS-S&P 500 flat as energy spike offsets tech slide Mar 07 2016
Valeant shares slide on news of probe by U.S. SEC Feb 29 2016
US STOCKS-S&P 500 falls below closely watched threshold Feb 29 2016
US open: Stocks slip at the start of trading Feb 29 2016
US pre-open: Stock futures fall on China slowdown worries Feb 29 2016
Valeant may have to restate revenues: WSJ Feb 22 2016
Valeant names interim chief while CEO on medical leave Jan 06 2016
US STOCKS-Wall Street cedes ground as oil decline deepens Dec 28 2015
US STOCKS-Wall Street loses ground as oil decline deepens Dec 28 2015
Ailing Valeant chief put on medical leave Dec 28 2015
Exclusive: Valeant considers selling contact lens maker Paragon - sources Dec 07 2015
Ackman boosts stake in drugmaker Valeant Nov 23 2015
Exclusive - ValueAct gains for the year wiped out by Valeant loss Nov 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)